An Along the Way item Tuesday mistakenly reported that the pair of red crowned cranes at Capron Park Zoo in Attleboro were ...

Regeneron is buying 23andMe’s consumer genetic-testing business, and says it plans to keep selling DNA tests to consumers. It’s also buying the 23andMe “Biobank,” a database of genetic ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. ... as Zaltrap has given way to Libtayo, their treatment for metastatic melanoma.

Regeneron's bid to purchase 23andMe, ... while furthering Regeneron’s efforts to use large-scale genetics research to improve the way society treats and prevents illness overall. ...

Regeneron is hoping a new program will widen patient access to its eye drug without also benefiting the company's rivals — a ...

Regeneron will pay $256 million in cash to acquire “substantially all” of 23andMe’s assets, excluding its telehealth business. At its peak in the fall of 2021, 23andMe had a stock-market ...

Regeneron Pharmaceuticals said Monday it will acquire 23andMe’s DNA testing business and most of its assets out of bankruptcy and pledged to continue offering the popular consumer service and ...

Although Regeneron has been playing catch-up in the oncology field for years, a pipeline built on next-wave promises could push the boundaries.

Regeneron Pharmaceuticals, a company that has been analyzing genetic data as part of its drug research for more than a decade, is augmenting its capabilities in a big way with the $256 million ...

After a seven-day trial, jurors sided with Regeneron on 10 of 11 claims, and awarded $135.6 million in compensatory damages—the top end of what Regeneron’s expert suggested—and another $271. ...

Regeneron Pharmaceuticals (NASDAQ: REGN) stock is trading above the $1,000 mark. It's at a high enough threshold that the company could decide to split its stock. That would lower the share price ...

Bankrupt DNA testing company 23andMe was purchased Monday by biotechnology company Regeneron for $256 million. Both companies insisted the sensitive genetic data provided to 23andMe by 15 million ...